Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SHE:300357)
China · Delayed Price · Currency is CNY 21.11
+0.24 (1.15%)
Oct 28, 2026, 3:04 PM CST
SHE:300357 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,119 | 1,062 | 925.39 | 848.19 | 896.02 | 807.69 |
Revenue Growth | 6.73% | 14.81% | 9.10% | -5.34% | 10.94% | 26.95% |
Gross Profit Gross Profit Growth | 1,066 | 1,012 | 880.58 | 808 | 853.5 | 773.25 |
Operating Income Operating Income Growth | 437.62 | 405.37 | 317.36 | 306.95 | 382.07 | 346.02 |
Net Income Net Income Growth | 427.36 | 380.94 | 317.82 | 310.18 | 348.77 | 337.99 |
Earnings Per Share EPS Growth | 0.82 | 0.73 | 0.61 | 0.59 | 0.67 | 0.65 |
EPS Growth | 9.46% | 19.87% | 2.46% | -11.06% | 3.19% | 21.38% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,534 | 1,432 | 1,315 | 1,289 | 1,136 | 1,021 |
Total Debt Total Debt Growth | 12.15 | 18.41 | 25.59 | 62.44 | 16.26 | 7.81 |
Net Cash (Debt) Net Cash Growth | 1,522 | 1,414 | 1,289 | 1,226 | 1,119 | 1,013 |
Net Cash Growth | 15.09% | 9.64% | 5.14% | 9.54% | 10.50% | 13.74% |
Net Cash Per Share Net Cash Per Share Growth | 2.91 | 2.70 | 2.46 | 2.34 | 2.14 | 1.93 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 481.13 | 423.2 | 262.44 | 382.08 | 360.28 | 360.58 |
Capital Expenditures CapEx Growth | -74.39 | -152.29 | -129.32 | -227.47 | -200.66 | -124.25 |
Free Cash Flow Free Cash Flow Growth | 406.75 | 270.9 | 133.12 | 154.61 | 159.62 | 236.33 |
Free Cash Flow Growth | 64.73% | 103.50% | -13.89% | -3.14% | -32.46% | 27.02% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Gross Margin | 95.25% | 95.24% | 95.16% | 95.26% | 95.25% | 95.74% |
Operating Margin | 39.11% | 38.16% | 34.29% | 36.19% | 42.64% | 42.84% |
Pretax Margin | 43.35% | 40.73% | 39.45% | 40.79% | 44.50% | 48.66% |
Profit Margin | 38.19% | 35.86% | 34.34% | 36.57% | 38.92% | 41.85% |
FCF Margin | 36.35% | 25.50% | 14.39% | 18.23% | 17.82% | 29.26% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.250 | 0.250 | 0.220 | 0.185 | 0.200 | 0.201 |
Dividend Per Share Growth | 13.64% | 13.64% | 18.92% | -7.50% | -0.50% | 25.62% |
Dividend Yield | 1.18% | 0.88% | 1.08% | 0.64% | 0.36% | 0.35% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 25.86 | 38.97 | 33.48 | 48.95 | 82.72 | 88.76 |
Forward PE | 24.40 | 33.35 | 26.80 | 38.41 | 62.09 | 69.52 |
P/FCF Ratio | 27.17 | 54.79 | 79.92 | 98.21 | 180.74 | 126.95 |
PS Ratio | 9.88 | 13.97 | 11.50 | 17.90 | 32.20 | 37.15 |